Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer

• Published in: Clinical lung cancer 2019-07, Vol.20 (4), p.e470-e479
• Main Authors: Voong, Khinh Ranh, Hazell, Sarah Z., Fu, Wei, Hu, Chen, Lin, Cheng Ting, Ding, Kai, Suresh, Karthik, Hayman, Jonathan, Hales, Russell K., Alfaifi, Salem, Marrone, Kristen A., Levy, Benjamin, Hann, Christine L., Ettinger, David S., Feliciano, Josephine L., Peterson, Valerie, Kelly, Ronan J., Brahmer, Julie R., Forde, Patrick M., Naidoo, Jarushka
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Anti–PD-1/PD-L1 therapy; B7-H1 Antigen - antagonists & inhibitors; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - epidemiology; Carcinoma, Non-Small-Cell Lung - radiotherapy; Drug-Related Side Effects and Adverse Reactions - epidemiology; Female; Follow-Up Studies; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - epidemiology; Lung Neoplasms - radiotherapy; Male; Middle Aged; Neoplasm Staging; Nivolumab; Nivolumab - therapeutic use; Pembrolizumab; Pneumonia - epidemiology; Pneumonia - etiology; Pneumonitis; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Radiation; Survival Analysis
• ISSN: 1525-7304; 1938-0690
• DOI: 10.1016/j.cllc.2019.02.018

To investigate the relationship between radiotherapy (RT), in particular chest RT, and development of immune-related (IR) pneumonitis in non–small-cell lung cancer (NSCLC) patients treated with anti–programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1). Between June 2011 and July 2017, NSCLC patients treated with anti–PD-1/PD-L1 at a tertiary-care academic cancer center were identified. Patient, treatment, prior RT (intent, technique, timing, courses), and IR pneumonitis details were collected. Treating investigators diagnosed IR pneumonitis clinically. Diagnostic IR pneumonitis scans were overlaid with available chest RT plans to describe IR pneumonitis in relation to prior chest RT. We evaluated associations between patient, treatment, RT details, and development of IR pneumonitis by Fisher exact and Wilcoxon rank-sum tests. Of the 188 NSCLC patients we identified, median follow-up was 6.78 (range, 0.30-79.3) months and median age 66 (range, 39-91) years; 54% (n = 102) were male; and 42% (n = 79) had stage I-III NSCLC at initial diagnosis. Patients received anti–PD-1/PD-L1 monotherapy (n = 127, 68%) or PD-1/PD-L1-based combinations (n = 61, 32%). In the entire cohort, 70% (132/188) received any RT, 53% (100/188) chest RT, and 37% (70/188) curative-intent chest RT. Any grade IR pneumonitis occurred in 19% (36/188; 95% confidence interval, 13.8-25.6). Of those who developed IR pneumonitis and received chest RT (n = 19), patients were more likely to have received curative-intent versus palliative-intent chest RT (17/19, 89%, vs. 2/19, 11%; P = .051). Predominant IR pneumonitis appearances were ground-glass opacities outside high-dose chest RT regions. No RT parameter was significantly associated with IR pneumonitis. On subset analysis of patients who developed IR pneumonitis and who had received prior chest RT, IR pneumonitis was more common in patients who received curative-intent chest RT. Attention should be paid to NSCLC patients receiving curative-intent RT followed by anti–PD-1/PD-L1 agents. In patients with non–small-cell lung cancer treated with anti–PD-1/PD-L1 agents, no specific radiation parameter was significantly associated with immune-related (IR) pneumonitis. We identify on subset analysis of patients who developed IR pneumonitis and received chest radiation, patients were numerically more likely to have received chest radiation with curative intent than with palliative intent (89% vs. 11%), that approached statistical significance